ArcticZymes Reports 15% Sales Growth in Q3 2026 Driven by Biomanufacturing
ArcticZymes Technologies recorded a 15% increase in third-quarter revenue to NOK 32.9 million, bolstered by a 44% rise in its biomanufacturing division.
ArcticZymes Technologies ASA announced its third-quarter financial results for 2026, reporting revenue of NOK 32.9 million. This represents a 15% increase year-over-year, or 24% when adjusted for constant currency exchange rates.
The growth was primarily fueled by the company's biomanufacturing segment, which saw a 44% increase in sales. This upward trend suggests a strengthening adoption of the firm's enzyme products within the manufacturing workflows of pharmaceutical developers.
For the first nine months of the year, cumulative sales reached NOK 96.6 million, a 23% rise compared to the same period in 2025. Financial performance improved significantly, with EBITDA for the nine-month period more than tripling to NOK 12.1 million.
These results reflect the company’s ongoing strategy to integrate its specialized enzymes into the production cycles of new medical therapies. As pharmaceutical firms increasingly incorporate these components into their manufacturing pipelines, ArcticZymes continues to position itself within the broader life sciences supply chain.